Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy

Published:2018-08-21 Issue:9 Volume:27 Page:741-751
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Fu Siqing¹,Wang Yudong¹²,Keyomarsi Khandan³,Meric-Bernstein Funda¹

Affiliation:

1. Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

2. Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, People’s Republic of China

3. Department of Experimental Radiation, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2018.1511700

Reference124 articles.

1. Cell cycle proteins as promising targets in cancer therapy

2. Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair

3. Whole–genome characterization of chemoresistant ovarian cancer

4. Targeting the replication stress response in cancer

5. Negative regulation of mitosis by wee1+, a gene encoding a protein kinase homolog

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DualSyn: A dual-level feature interaction method to predict synergistic drug combinations;Expert Systems with Applications;2024-12

2. Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities;Experimental Hematology & Oncology;2024-08-05

3. Population Pharmacokinetic Modeling of Adavosertib (AZD1775) in Patients with Solid Tumors;The Journal of Clinical Pharmacology;2024-07-19

4. Antibody–drug conjugates in gastric cancer: from molecular landscape to clinical strategies;Gastric Cancer;2024-07-04

5. Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia;Genome Biology;2024-05-31

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3